Edition:
United States

Amarin Corporation PLC (AMRN.O)

AMRN.O on Consolidated Issue listed on NASDAQ Global Market

3.33USD
23 Feb 2017
Change (% chg)

$-0.05 (-1.48%)
Prev Close
$3.38
Open
$3.39
Day's High
$3.39
Day's Low
$3.16
Volume
2,448,886
Avg. Vol
2,029,517
52-wk High
$3.65
52-wk Low
$1.34

AMRN.O

Chart for AMRN.O

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $898.94
Shares Outstanding(Mil.): 269.95
Dividend: --
Yield (%): --

Financials

  AMRN.O Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -0.43 -- --
ROI: -65.71 -3.18 12.94
ROE: -- 5.86 14.09

BRIEF-Amarin says debt restructuring and related private placement of exchangeable senior notes

* Amarin announces debt restructuring and related private placement of exchangeable senior notes

Jan 20 2017

BRIEF-Amarin Q3 adjusted non-gaap loss per share $0.08

* Maintaining guidance on 2016 net product revenue at $112-$125 million

Nov 03 2016

CORRECTED-BRIEF-Amarin REDUCE-IT cardiovascular outcomes study to continue without changes

* Reduce-It cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee

Sep 12 2016

BRIEF-Amarin randomizes final patient into reduce-it cardiovascular outcomes study of Vascepa

* Amarin randomizes final patient into reduce-it cardiovascular outcomes study of Vascepa

Aug 31 2016

BRIEF-Amarin Corporation announces mandatory exchange of some senior notes

* Amarin announces mandatory exchange of exchangeable senior notes issued in may 2014 and november 2015

Aug 26 2016

More From Around the Web

Competitors

Earnings vs. Estimates